Saltar al contenido
Merck

Hepatic vitamin A preloading reduces colorectal cancer metastatic multiplicity in a mouse xenograft model.

Nutrition and cancer (2012-05-31)
Eun Young Park, Daniel Pinali, Krista Lindley, Michelle A Lane
RESUMEN

Previous research in our laboratory showed that retinol inhibited all-trans retinoic acid (ATRA)-resistant human colon cancer cell invasion via a retinoic acid receptor-independent mechanism in vitro. The objective of the current study was to determine if dietary vitamin A supplementation inhibited metastasis of ATRA-resistant colon cancer cells in a nude mouse xenograft model. Female nude mice (BALB/cAnNCr-nu/nu, n = 14 per group) consumed a control diet (2,400 IU retinyl palmitate/kg diet) or a vitamin A supplemented diet (200,000 IU retinyl palmitate/kg diet) for 1 mo prior to tumor cell injection to preload the liver with vitamin A. HCT-116, ATRA-resistant, human colon cancer cells were intrasplenically injected. Mice continued to consume their respective diets for 5 wk following surgery. Consumption of supplemental vitamin A decreased hepatic metastatic multiplicity to 17% of control. Hepatic and splenic retinol and retinyl ester concentrations were significantly higher in the mice supplemented with vitamin A when compared to mice consuming the control diet. Supplemental vitamin A did not decrease body weight, feed intake, or cause toxicity. Thus, supplemental dietary vitamin A may decrease the overall number of hepatic metastasis resulting from colon cancer.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
Retinyl Palmitate (Vitamin A Palmitate), Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Retinyl palmitate, potency: ≥1,700,000 USP units per g
Supelco
Retinol palmitate, analytical standard
Sigma-Aldrich
Retinyl palmitate, Type IV, ~1,800,000 USP units/g, oil